

Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies

Max V. Boot,^{1,2} Michael Schaapveld,³ Esther C. van den Broek,⁴ the PALGA Group⁴, Nathalie J. Hijmering,¹ Kimberly van der Oord,⁵ Flora E. van Leeuwen,³ Avinash G. Dinmohamed,^{6,7,8} Lianne Koens¹ and Daphne de Jong¹

¹Amsterdam UMC, Department of Pathology, Amsterdam; ²Reinier Haga MDC, Department of Pathology, Delft; ³Department of Epidemiology, Netherlands Cancer Institute, Amsterdam; ⁴Dutch Pathology Registry (PALGA), Houten; ⁵Laboratorium Pathologie Oost-Nederland (LABPON), Hengelo; ⁶Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht; ⁷Department of Public Health, Erasmus MC, Erasmus University Medical Center, Rotterdam and ⁸Amsterdam UMC, Department of Hematology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands

Correspondence: M.V. Boot
max.boot@reinier-mdc.nl

Received: March 4, 2022.

Accepted: July 14, 2022.

Early view: October 20, 2022.

<https://doi.org/10.3324/haematol.2022.280840>

©2023 Ferrata Storti Foundation

Published under a CC-BY-NC license



SUPPLEMENTARY TABLE LEGEND (see table in the excel file)

Table S1: Detailed information regarding reviewed cases.

Table showing detailed information on clinical parameters, material availability and diagnostic arguments and decisions of all cases with reported non-Hodgkin lymphoma subsequent to classic Hodgkin lymphoma.

-: no expression, +: strong expression; AITL: Angio-immunoblastic T-cell lymphoma; ALCL: Anaplastic large cell lymphoma; B-ALL: B-cell acute lymphoblastic leukemia; CHL: classical Hodgkin lymphoma; CLL: Chronic lymphoid leukemia; dim+: weak expression; DLBCL: Diffuse large B-cell lymphoma; Equivocal: Highly likely diagnosis but cannot be further proven due to lack of sufficient material and/or clinical information; HGBCL, TH: High grade large B-cell lymphoma, triple hit; ID-LBCL: Immunodeficiency-related large B-cell lymphoma; LPL: lymphoplasmacytic lymphoma; MGZL: Mediastinal grey zone lymphoma; Mono-like hyperplasia: Mononucleosis-like lymphoid hyperplasia; NHL: non-Hodgkin lymphoma; n/a: data not available; NMZL: Nodal marginal zone lymphoma; PCFLCL: Primary cutaneous follicle center cell lymphoma; PMBCL: Primary mediastinal large B-cell lymphoma; PTCL, NOS: Peripheral T-cell lymphoma not otherwise specified; PTCL, TFH: Peripheral T-cell lymphoma, T-follicular helper cell phenotype; Unequivocal: diagnosis fully supported by objective criteria.